A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies
OPEN TO ACCRUAL
I
NCT05544019
aolszewski@BrownHealth.org
